JP4860469B2 - 新規シルデナフィル遊離塩基組成物 - Google Patents

新規シルデナフィル遊離塩基組成物 Download PDF

Info

Publication number
JP4860469B2
JP4860469B2 JP2006521069A JP2006521069A JP4860469B2 JP 4860469 B2 JP4860469 B2 JP 4860469B2 JP 2006521069 A JP2006521069 A JP 2006521069A JP 2006521069 A JP2006521069 A JP 2006521069A JP 4860469 B2 JP4860469 B2 JP 4860469B2
Authority
JP
Japan
Prior art keywords
less
composition
free base
sildenafil
nanoparticulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006521069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528176A5 (https=
JP2006528176A (ja
Inventor
ツーラ エー． ライド
ダグラス シー． ハービ
エイチ． ウィリアム ボッシュ
Original Assignee
エラン ファーマ インターナショナル，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エラン ファーマ インターナショナル，リミティド filed Critical エラン ファーマ インターナショナル，リミティド
Publication of JP2006528176A publication Critical patent/JP2006528176A/ja
Publication of JP2006528176A5 publication Critical patent/JP2006528176A5/ja
Application granted granted Critical
Publication of JP4860469B2 publication Critical patent/JP4860469B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2006521069A 2003-07-23 2004-07-23 新規シルデナフィル遊離塩基組成物 Expired - Fee Related JP4860469B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48910103P 2003-07-23 2003-07-23
US60/489,101 2003-07-23
PCT/US2004/019106 WO2005013937A2 (en) 2003-07-23 2004-07-23 Novel compositions of sildenafil free base

Publications (3)

Publication Number Publication Date
JP2006528176A JP2006528176A (ja) 2006-12-14
JP2006528176A5 JP2006528176A5 (https=) 2011-02-17
JP4860469B2 true JP4860469B2 (ja) 2012-01-25

Family

ID=34135095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006521069A Expired - Fee Related JP4860469B2 (ja) 2003-07-23 2004-07-23 新規シルデナフィル遊離塩基組成物

Country Status (8)

Country Link
US (1) US20050042177A1 (https=)
EP (1) EP1658053B1 (https=)
JP (1) JP4860469B2 (https=)
AT (1) ATE387186T1 (https=)
CA (1) CA2533163A1 (https=)
DE (1) DE602004012117T2 (https=)
ES (1) ES2302035T3 (https=)
WO (1) WO2005013937A2 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080102121A1 (en) * 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
CA2475092C (en) * 2002-02-04 2012-05-01 Baudax Bio, Inc. Nanoparticulate compositions having lysozyme as a surface stabilizer
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
CA2519287A1 (en) 2003-03-27 2004-10-14 Bioactis Limited Powder medicine applicator for nasal cavity
ATE387203T1 (de) 2004-01-05 2008-03-15 Teva Pharma Prozesse zur herstellung von sildenafil-base und zitratsalz
AU2005249494A1 (en) 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
CN101094659A (zh) * 2004-12-31 2007-12-26 伊休蒂卡有限公司 纳米微粒组合物及其合成方法
AU2012201630B8 (en) * 2004-12-31 2014-03-06 Iceutica Pty Ltd NanoParticle Composition(s) and Method for Synthesis Thereof
US20090074796A1 (en) 2005-01-07 2009-03-19 The John Hopkins University Pde5 inhibitor compositions and methods for immunotherapy
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
EP1871345B1 (en) 2005-04-12 2012-08-01 Elan Pharma International Limited Nanoparticulate erlotinib formulations
DE102005016981A1 (de) * 2005-04-13 2006-10-19 Bayer Healthcare Ag Kombination zur Therapie bei benigner Prostatahyperplasie
KR20080008403A (ko) * 2005-05-10 2008-01-23 엘란 파마 인터내셔널 리미티드 나노입자형 클로피도그렐 제제
US20110064803A1 (en) * 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
BRPI0611075A2 (pt) * 2005-06-03 2010-08-03 Elan Pharma Int Ltd formulações de acetaminofeno em nanopartìcula
ES2341996T3 (es) * 2005-06-03 2010-06-30 Elan Pharma International Limited Formulaciones de mesilato de imatinib en forma de manoparticulas.
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
EP1954253A4 (en) 2005-06-08 2011-07-27 Elan Pharma Int Ltd NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
EP1898882B1 (en) * 2005-06-09 2009-10-28 Elan Pharma International Limited Nanoparticulate ebastine formulations
CA2611741A1 (en) * 2005-06-13 2006-12-28 Elan Pharma International, Limited Nanoparticulate clopidogrel and aspirin combination formulations
JP2008543862A (ja) * 2005-06-15 2008-12-04 エラン ファーマ インターナショナル リミテッド ナノ粒子アゼルニジピン製剤
JP2008546786A (ja) * 2005-06-23 2008-12-25 シェーリング コーポレイション Ｐｄｅ５インヒビターの迅速吸収性経口処方物
JP2008518041A (ja) * 2005-08-29 2008-05-29 テバ ファーマシューティカル インダストリーズ リミティド 双峰性粒度分布を有する固体微粒子タダラフィル
US20070104792A1 (en) * 2005-09-13 2007-05-10 Elan Pharma International, Limited Nanoparticulate tadalafil formulations
CA2622758A1 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
WO2007056457A2 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US20080261995A1 (en) * 2005-12-21 2008-10-23 Pfizer Inc. Pharmaceutical Combination of a Pde-5 Inhibitor and a 5-Alpha Reductase Inhibitor
DK1984344T3 (da) 2005-12-29 2013-01-14 Lexicon Pharmaceuticals Inc Multicykliske aminosyrederivater og fremgangsmåder til anvendelse heraf
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
JP2009538927A (ja) 2006-05-30 2009-11-12 エラン ファーマ インターナショナル，リミティド ナノ粒子状のポサコナゾール製剤
DK2054042T3 (da) * 2006-06-30 2020-08-03 Iceutica Pty Ltd Fremgangsmåder til fremstilling af biologisk aktive forbindelser i nanopartikelform
JP2009543797A (ja) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
KR20090031618A (ko) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 나노입자형 모다피닐 제제
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
CN101668544B (zh) 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
WO2008091855A1 (en) * 2007-01-22 2008-07-31 Novavax, Inc. Multi-phasic pharmaceutical formulations of poorly water-soluble drugs for reduced fed/fasted variability and improved oral bioavailability
KR100920106B1 (ko) * 2007-11-14 2009-10-01 경북대학교 산학협력단 구연산 실데나필을 경피적으로 전달하기 위한 조절 약물전달체 및 이를 포함하는 경피 패치
MX2010009848A (es) * 2008-03-21 2010-09-30 Elan Pharma Int Ltd Composiciones para el suministro especifico en sitio de imatinib y metodos de uso.
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
AU2010239081C1 (en) 2009-04-24 2014-11-06 Iceutica Pty Ltd A novel formulation of indomethacin
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
HUE032426T2 (en) 2009-05-27 2017-09-28 Alkermes Pharma Ireland Ltd Inhibition of flake aggregation in nanoparticulate meloxicam formulations
SG177281A1 (en) 2009-06-19 2012-02-28 Nanoform Hungary Ltd Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
GB2472327B (en) * 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
AU2010315190A1 (en) 2009-11-05 2012-05-10 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of cancer
CA2789229A1 (en) 2010-02-10 2011-08-18 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
CA2802047C (en) * 2010-06-07 2019-05-07 Novadel Pharma Inc. Oral spray formulations and methods for administration of sildenafil
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN102127182B (zh) * 2010-12-23 2012-07-04 南京医科大学 用于检测pde-5抑制剂的磁性分子印记聚合物的制备方法
MA34960B1 (fr) * 2011-02-11 2014-03-01 Ctc Bio Inc Preparation de film contenant une base sans sidenafil et son procede
WO2013148978A1 (en) 2012-03-30 2013-10-03 Lexicon Pharmaceuticals, Inc. Methods and compositions for the treatment of necrotizing enterocolitis
FR2999086B1 (fr) * 2012-12-10 2015-04-10 Ethypharm Sa Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
WO2014125343A1 (en) * 2013-02-12 2014-08-21 Alembic Pharmaceuticals Limited Tadalafil tablet composition with reduced dose strength
WO2015010205A1 (en) 2013-07-22 2015-01-29 Université Du Québec À Chicoutimi Use of plant extracts against herpes simplex virus
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
WO2017168174A1 (en) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
KR101778688B1 (ko) 2016-05-31 2017-09-15 한양대학교 에리카산학협력단 포스포다이에스터라제―5 억제제를 포함하는 약제학적 복합제제
EP3576741A1 (en) 2017-02-02 2019-12-11 Dukebox SP. Z O.O. A method of manufacturing a suspension of nanoparticles of tadalafil or sildenafil citrate
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
WO2019130052A1 (en) * 2017-12-26 2019-07-04 Ftf Pharma Private Limited Liquid oral formulations for pde v inhibitors
GR1009643B (el) * 2018-06-25 2019-11-12 Arvo Μονοπροσωπη Ι.Κ.Ε. Νεες συνθεσεις φαρμακευτικων σκευασματων σιλδεναφιλης μειωμενης περιεκτικοτητας σε δραστικη ουσια και νεες χρησεις τους
CN112972404A (zh) * 2019-12-02 2021-06-18 北京兴源联合医药科技有限公司 一种西地那非冻干口腔崩解片及其制备方法
CN112972405B (zh) * 2019-12-02 2022-12-27 北京兴源联合医药科技有限公司 一种他达拉非冻干口腔崩解片及其制备方法
PL3928772T3 (pl) 2020-06-26 2024-10-07 Algiax Pharmaceuticals Gmbh Kompozycja nanocząstkowa
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022103638A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Cannabinoids in the treatment of autism spectrum disorder
WO2023037394A1 (en) * 2021-09-13 2023-03-16 Amman Pharmaceutical Industries Company A pharmaceutical composition of sildenafil and a formulation thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04295420A (ja) * 1991-01-25 1992-10-20 Sterling Winthrop Inc 表面変性薬物微小粒子
JP2002538099A (ja) * 1999-03-03 2002-11-12 エラン ファーマ インターナショナル，リミティド ナノパーティクル組成物用の表面安定剤としてのｐｅｇ誘導体化脂質の使用
WO2002094219A2 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of erectile dysfunction drugs through an inhalation route
WO2002098390A2 (en) * 2001-06-05 2002-12-12 Alexza Molecular Delivery Corporation Delivery of aerosols containing small particles through an inhalation route
JP2003511406A (ja) * 1999-10-08 2003-03-25 エラン ファーマ インターナショナル，リミティド 陽イオン性表面安定剤を有する生体付着性ナノ粒子組成物
WO2003024424A1 (en) * 2001-09-14 2003-03-27 Elan Pharma International Ltd. Stabilization of active agents by formulation into nanoparticulate form

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3315356A1 (de) * 1982-04-30 1983-11-17 Ono Pharmaceutical Co. Ltd., Osaka Verwendung von prostaglandinanalogen
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
US6531114B1 (en) * 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US20010053780A1 (en) * 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
CA2391968A1 (en) * 1999-11-18 2001-05-25 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
EP1289526A4 (en) * 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
CA2417736A1 (en) * 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
US6548508B2 (en) * 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
GB0219516D0 (en) * 2002-08-21 2002-10-02 Phoqus Ltd Fast dissolving and taste masked oral dosage form comprising sildenafil

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04295420A (ja) * 1991-01-25 1992-10-20 Sterling Winthrop Inc 表面変性薬物微小粒子
JP2002538099A (ja) * 1999-03-03 2002-11-12 エラン ファーマ インターナショナル，リミティド ナノパーティクル組成物用の表面安定剤としてのｐｅｇ誘導体化脂質の使用
JP2003511406A (ja) * 1999-10-08 2003-03-25 エラン ファーマ インターナショナル，リミティド 陽イオン性表面安定剤を有する生体付着性ナノ粒子組成物
WO2002094219A2 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of erectile dysfunction drugs through an inhalation route
WO2002098390A2 (en) * 2001-06-05 2002-12-12 Alexza Molecular Delivery Corporation Delivery of aerosols containing small particles through an inhalation route
WO2003024424A1 (en) * 2001-09-14 2003-03-27 Elan Pharma International Ltd. Stabilization of active agents by formulation into nanoparticulate form

Also Published As

Publication number Publication date
US20050042177A1 (en) 2005-02-24
ES2302035T3 (es) 2008-07-01
JP2006528176A (ja) 2006-12-14
CA2533163A1 (en) 2005-02-17
ATE387186T1 (de) 2008-03-15
WO2005013937A2 (en) 2005-02-17
EP1658053A2 (en) 2006-05-24
DE602004012117T2 (de) 2009-02-26
WO2005013937A3 (en) 2005-06-16
DE602004012117D1 (de) 2008-04-10
EP1658053B1 (en) 2008-02-27

Similar Documents

Publication Publication Date Title
JP4860469B2 (ja) 新規シルデナフィル遊離塩基組成物
JP4611641B2 (ja) Ｍａｐキナーゼ阻害剤のナノ粒子組成物
JP4469846B2 (ja) ナノ粒子状トピラメート製剤
US9101549B2 (en) Nanoparticulate megestrol formulations
JP5548092B2 (ja) ナノ粒子のメロキシカム製剤
JP2009507925A (ja) ナノ粒子タダラフィル製剤
JP2009508859A (ja) ナノ粒子アリピプラゾール製剤
JP2009518300A (ja) モメタゾン組成物ならびにその作製方法および使用方法
JP2005529911A (ja) ナノ粒子ナイスタチン製剤
JP2011121972A (ja) フルチカゾン製剤
KR20090015994A (ko) 나노입자형 포사코나졸 제제
JP2008542397A (ja) ナノ粒子メシル酸イマチニブ製剤
JP2010248220A (ja) ナノ粒子メゲストロール製剤
KR20080017065A (ko) 나노입자형 아세트아미노펜 제제
US20120087955A1 (en) Nanoparticulate megestrol formulations
JP2008546796A (ja) ナノ微粒子メゲストロール製剤
EP1855651A1 (en) Nanoparticulate compositions of heterocyclic amide derivatives

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101209

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111012

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111102

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141111

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees